Manganese: Lyme Disease’s Unexpected Weakness Discovered by Researchers
Table of Contents
A new study reveals that manganese, a key component in the defense system of the Lyme disease bacterium, Borrelia burgdorferi, is also its critical vulnerability, potentially paving the way for novel treatment strategies.
For decades, Lyme disease has posed a significant challenge to both physicians and patients. Caused by the corkscrew-shaped bacterium Borrelia burgdorferi, the infection can cause fever, fatigue, and painful inflammation if left untreated, often lingering for months. Now, scientists at Northwestern University and the Uniformed Services University (USU) have identified a surprising weakness in this resilient pathogen.
The Double-Edged Sword of Manganese
Researchers discovered that manganese plays a paradoxical role in the bacterium’s survival. While it shields B. burgdorferi from the host’s immune system, manipulating manganese levels – either depriving the bacteria of it or overloading it – renders it highly susceptible to both the immune response and conventional treatments.
“Our work shows that manganese is a double-edged sword in Lyme disease,” explained a lead researcher. “It’s both Borrelia’s armor and its weakness. If we can target the way it manages manganese, we could open doors for entirely new approaches for treating Lyme disease.”
Unveiling the Bacterial Defense System
The team utilized advanced imaging techniques – electron paramagnetic resonance (EPR) and electron nuclear double resonance (ENDOR) spectroscopy – to create a detailed “map” of manganese within the living bacteria. This revealed a two-tiered defense system. First, the bacteria employ an enzyme called MnSOD, acting as a primary shield against the host’s immune attack. Any oxygen radicals that bypass this shield are then neutralized by a pool of manganese metabolites, functioning like a sponge to absorb toxic molecules.
According to researchers, the bacteria are in a constant state of balancing manganese distribution between these two systems. However, as the bacteria age, their metabolite pools shrink, leaving them vulnerable. At this stage, an excess of manganese becomes toxic, as the bacteria lose their capacity to safely store it.
Rising Lyme Disease Rates and the Need for New Therapies
The increasing prevalence of Lyme disease underscores the urgency for innovative treatment options. Since the 1980s, the incidence of Lyme disease has risen dramatically across North America and globally. The Centers for Disease Control and Prevention estimates roughly 476,000 people in the United States are diagnosed annually. Currently, there are no approved vaccines, and long-term antibiotic use presents challenges, as antibiotics can disrupt the beneficial bacteria in the gut.
“Although antibiotics harm B. burgdorferi, they also kill beneficial gut bacteria,” one researcher noted. “Lyme disease is transmitted through tick bites and – if not treated promptly – can cause lingering effects by attacking the patient’s immune, circulatory and central nervous systems.”
Future Therapeutic Strategies
This discovery opens promising avenues for future Lyme disease therapies. Researchers suggest potential strategies include developing drugs that starve the bacterium of manganese, disrupt its ability to form protective manganese complexes, or even induce toxic overload. Any of these approaches would leave B. burgdorferi vulnerable to attack by the host’s immune system.
“By disrupting the delicate balance of manganese in B. burgdorferi, it may be possible to weaken the pathogen during infection,” a researcher stated. “Manganese is an Achilles’ heel of its defenses.”
The study is scheduled for publication on Thursday, November 13, in the journal mBio. The research was supported by [Funding source information would be included here if available].
Journal reference: Londoño, A. F., et al. (2025). EPR spectroscopy reveals antioxidant manganese defenses in the Lyme disease pathogen Borrelia burgdorferi. mBio. doi: 10.1128/mbio.02824-25. https://journals.asm.org/doi/10.1128/mbio.02824-25.
